Recombinant poxviruses as mucosal vaccine vectors

Area of Science:

• Immunology
• Vaccinology
• Virology

Background:

• Most infections originate at mucosal surfaces, necessitating robust mucosal immunity for vaccine development.
• Poxvirus vectors, particularly modified vaccinia virus Ankara (MVA), are potent tools for inducing immune responses against foreign antigens.
• MVA-based vectors have shown promise in preclinical models for respiratory viruses, HIV, and tuberculosis.

Purpose of the Study:

• To review studies utilizing recombinant MVA (rMVA) as a vector for mucosal antigen delivery.
• To evaluate the efficacy of rMVA in stimulating mucosal immunity against various pathogens.
• To highlight the potential of rMVA for developing vaccines against mucosal infections.

Main Methods:

• Review of existing literature on recombinant poxviruses, specifically rMVA.
• Analysis of studies involving mucosal delivery of rMVA in murine and macaque models.
• Examination of rMVA's role in prime-boost vaccination strategies.

Main Results:

• rMVA effectively induces specific immune responses at mucosal surfaces, including the genital and rectal tracts.
• rMVA delivery has shown control of simian/human immunodeficiency virus viraemia and disease progression.
• Intranasal rMVA delivery is crucial for protective immunity against Mycobacterium tuberculosis.

Conclusions:

• rMVA is a promising vector for inducing mucosal immunity against diverse pathogens.
• Further research is warranted to fully characterize and enhance the mucosal immunogenicity of MVA-based poxvirus vectors.
• rMVA holds significant potential for the development of next-generation vaccines targeting mucosal infections.